1. Home
  2. CHY vs VSTM Comparison

CHY vs VSTM Comparison

Compare CHY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

N/A

Current Price

$10.61

Market Cap

960.4M

Sector

Finance

ML Signal

N/A

Logo Verastem Inc.

VSTM

Verastem Inc.

N/A

Current Price

$8.28

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHY
VSTM
Founded
2003
2010
Country
United States
United States
Employees
N/A
102
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
960.4M
1.1B
IPO Year
2003
2011

Fundamental Metrics

Financial Performance
Metric
CHY
VSTM
Price
$10.61
$8.28
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $17.22
AVG Volume (30 Days)
201.8K
★ 3.8M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 10.11%
N/A
EPS Growth
N/A
★ 17.49
EPS
★ N/A
N/A
Revenue
N/A
★ $30,914,000.00
Revenue This Year
N/A
$262.65
Revenue Next Year
N/A
$38.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 209.14
52 Week Low
$10.41
$3.43
52 Week High
$13.91
$10.82

Technical Indicators

Market Signals
Indicator
CHY
VSTM
Relative Strength Index (RSI) 35.06 42.54
Support Level $10.41 $7.10
Resistance Level $12.21 $8.59
Average True Range (ATR) 0.22 0.55
MACD 0.01 -0.21
Stochastic Oscillator 5.95 22.53

Price Performance

Historical Comparison
CHY
VSTM

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: